B
DFTX

Bailard’s Definium Therapeutics DFTX Stock Holding History

Bailard’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
+6,277
New +$155K 0.01% 645
2025
Q3 		– Sell
-14,600
Closed -$94.8K – 845
2025
Q2 		$94.8K Hold
14,600
– – ﹤0.01% 741
2025
Q1 		$85.4K Hold
14,600
– – ﹤0.01% 722
2024
Q4 		$102K Sell
14,600
-9,500
-39% -$65.4K ﹤0.01% 716
2024
Q3 		$137K Hold
24,100
– – ﹤0.01% 721
2024
Q2 		$174K Hold
24,100
– – ﹤0.01% 695
2024
Q1 		$227K Buy
24,100
+6,800
+39% +$38.8K 0.01% 658
2023
Q4 		$63.3K Buy
+17,300
New +$52.1K ﹤0.01% 698

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bailard's DFTX Position: Q2 2026 in Review

Bailard opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 6,277 shares worth $295K. The stake represents 0.01% of the portfolio and ranks #645 among its holdings. This is a return to the name: Bailard previously reported a position in DFTX as recently as Q2 2025.

Bailard first reported a position in DFTX in Q4 2023 and has held it in 8 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Bailard held 6,277 shares of Definium Therapeutics worth $295K as of Q2 2026.
  • Definium Therapeutics was a new Bailard position in Q2 2026.
  • Definium Therapeutics made up 0.01% of Bailard's portfolio in Q2 2026, its #645 holding.
  • Bailard first reported a position in Definium Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.